Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

2-hydroxy docosahexaenoic acid - Laminar Pharmaceuticals

Next Previous
Drug Profile

2-hydroxy docosahexaenoic acid - Laminar Pharmaceuticals

Alternative Names: DHA-H; LAM-226; LP-226A1

Latest Information Update: 27 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Laminar Pharmaceuticals
  • Class Antidementias; Neuroprotectants; Omega 3 fatty acids
  • Mechanism of Action Membrane lipid modulators; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; CNS disorders; Neurodegenerative disorders

Most Recent Events

  • 27 Feb 2024 2-hydroxy docosahexaenoic acid is still in preclinical trials for Alzheimer's disease, CNS disorders and Neurodegenerative disease in Spain (Laminar Pharmaceuticals pipeline, February 2024)
  • 28 May 2023 No recent reports of development identified for preclinical development in CNS-disorders in Spain (PO)
  • 14 Oct 2022 Laminar Pharmaceuticals plans to launch 2-hydroxy docosahexaenoic acid in 2027 or 2028 (Laminar Pharmaceuticals, October 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top